{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ocrelizumab&page=2", "query": { "intervention": "ocrelizumab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ocrelizumab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T15:19:57.911Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04047628", "title": "Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis", "Relapsing Remitting Multiple Sclerosis", "Secondary Progressive Multiple Sclerosis" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Best Available Therapy (BAT)", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 156, "start_date": "2020-08-17", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-28T15:19:57.911Z", "location_count": 23, "location_summary": "Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04047628" }, { "nct_id": "NCT07074886", "title": "A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab Test Formulation", "type": "DRUG" }, { "name": "Ocrelizumab Reference Formulation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 193, "start_date": "2025-11-13", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-09-28T15:19:57.911Z", "location_count": 9, "location_summary": "Carlsbad, California • Fort Collins, Colorado • Maitland, Florida + 6 more", "locations": [ { "city": "Carlsbad", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Maitland", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07074886" }, { "nct_id": "NCT05232825", "title": "A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis", "Primary Progressive Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab IV", "type": "DRUG" }, { "name": "Ocrelizumab SC", "type": "DRUG" }, { "name": "Methylprednisolone IV", "type": "DRUG" }, { "name": "Diphenhydramine IV", "type": "DRUG" }, { "name": "Dexamethasone given orally", "type": "DRUG" }, { "name": "Desloratadine given orally", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 236, "start_date": "2022-05-03", "completion_date": "2025-06-06", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-28T15:19:57.911Z", "location_count": 7, "location_summary": "Maitland, Florida • Tampa, Florida • Baltimore, Maryland + 4 more", "locations": [ { "city": "Maitland", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Owosso", "state": "Michigan" }, { "city": "Dayton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05232825" }, { "nct_id": "NCT00808210", "title": "A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Infliximab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2009-03-05", "completion_date": "2012-11-14", "has_results": true, "last_update_posted_date": "2020-11-06", "last_synced_at": "2026-09-28T15:19:57.911Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Murrieta", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00808210" }, { "nct_id": "NCT04834401", "title": "Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis", "Covid19" ], "interventions": [], "intervention_types": [], "sponsor": "St. Barnabas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 45, "start_date": "2021-03-22", "completion_date": "2022-05-17", "has_results": false, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-09-28T15:19:57.911Z", "location_count": 1, "location_summary": "Livingston, New Jersey", "locations": [ { "city": "Livingston", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04834401" }, { "nct_id": "NCT03025269", "title": "Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 30, "start_date": "2017-11-15", "completion_date": "2022-01-08", "has_results": false, "last_update_posted_date": "2022-03-11", "last_synced_at": "2026-09-28T15:19:57.911Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03025269" }, { "nct_id": "NCT06677710", "title": "IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis", "Primary Progressive Multiple Sclerosis (PPMS)", "Secondary Progressive Multiple Sclerosis (SPMS)", "Non-Active Secondary Progressive Multiple Sclerosis", "Non-Active SPMS", "Autoimmune Diseases of the Nervous System", "Nervous System Diseases", "Autoimmune Diseases", "Demyelinating Diseases", "Immune System Diseases", "Demyelinating Autoimmune Diseases, Central Nervous System (CNS)" ], "interventions": [ { "name": "IDP-023", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indapta Therapeutics, INC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 34, "start_date": "2026-06-30", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-09-28T15:19:57.911Z", "location_count": 5, "location_summary": "Stanford, California • Aurora, Colorado • Orlando, Florida + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06677710" }, { "nct_id": "NCT04377555", "title": "Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Multiple Sclerosis, Relapsing" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 179, "start_date": "2020-07-30", "completion_date": "2025-11-11", "has_results": false, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-09-28T15:19:57.911Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04377555" }, { "nct_id": "NCT04035005", "title": "A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Primary Progressive" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1013, "start_date": "2019-08-12", "completion_date": "2028-01-19", "has_results": true, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-09-28T15:19:57.911Z", "location_count": 8, "location_summary": "Washington D.C., District of Columbia • Clearwater, Florida • Orlando, Florida + 5 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Vero Beach", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04035005" }, { "nct_id": "NCT07207148", "title": "People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "GLP-1", "type": "DRUG" }, { "name": "Ocrelizumab (US)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 100, "start_date": "2025-11-15", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-09-28T15:19:57.911Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07207148" } ] }